This study looks at how well a new combination treatment works for people with non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The combination is Sigvotatug Vedotin with pembrolizumab, compared to pembrolizumab alone. The goal is to see which option helps patients better.
The trial's ID number is NCT06758401. This is a Phase 3 trial, which means it is looking at how well the treatment works and how safe it is. The study is FDA-regulated and aims to include about 714 participants.
Who can join
Adults aged 18 and older can join the study. It is open to both men and women. Participants must have non-small cell lung cancer that cannot be surgically removed. They must also have high levels of PD-L1 in their cancer cells. The study team will check to confirm who is eligible.
The study team makes the final call on eligibility.
What happens in the study
Everyone in the study will receive pembrolizumab through an intravenous (IV) infusion every 6 weeks. Half of the participants will also receive Sigvotatug Vedotin as an IV infusion every 2 weeks. Participants will be monitored closely during regular visits to the clinic.
Where
This trial is enrolling at 58 locations. Recruiting sites are listed first.
American Oncology Network Vista Oncology Division-East office
Olympia, Washington
Recruiting
American Oncology Network Vista Oncology Division-West office
Olympia, Washington
Recruiting
BRCR Global
Plantation, Florida
Recruiting
Cancer Centers of Colorado St. Mary's Regional Hospital
Grand Junction, Colorado
Recruiting
Cancer Partners of Nebraska - April Sampson Cancer Center
Chief of Thoracic Surgery and Director of the Lung Cancer Program at West Virginia University Cancer Institute. Treats lung cancer and esophageal cancer.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led the National Lung Screening Trial. Treats lung cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.